NST research

Creatine monohydrate: what it does, who it helps, and what it can't do

Creatine monohydrate is one of the most studied training supplements. Combined with resistance training it produces a small increase in strength and muscle size, it appears well tolerated in healthy adults, and it is optional rather than essential.
Research-basedReviewed by Gabriel SilvaLast verified 12 September 2026Next review due 14 March 2027Report a correction

The evidence-led answer

The short answer

If you do resistance training, taking creatine monohydrate tends to add a little on top of what training alone gives you: slightly more strength, and a small increase in muscle size. The effect is real but modest, and it is an add on to training, not a substitute for it. In healthy adults, the doses people normally use have not been shown to harm the kidneys or cause the problems creatine is often blamed for. You do not need it to make progress, and you do not need an expensive version of it.

What creatine is

Creatine is a compound your body already makes (mainly in the liver and kidneys) and that you also get from meat and fish. Most of it is stored in muscle, where it helps recycle the molecule muscles use for very short, hard efforts. Supplementing raises the amount stored in muscle, which is the mechanism thought to underlie its effects on training. Creatine monohydrate is the original, most tested form. It is a food supplement, not a medicine.

What the evidence shows for strength and muscle

When creatine is added to a resistance training programme, reviews of randomised trials find a small advantage over training with a placebo, for both strength and muscle size. The people studied include trained and untrained adults, older adults, and women. In postmenopausal women, a 2026 pooled analysis found small gains in lean mass (about +0.37 kg) and leg press strength when creatine (5 g/day or more) was combined with resistance training, with no measurable effect on bone density and no change in kidney markers. Two honest caveats: the effect sizes are small, and not everyone responds the same way.

Two pooled analyses of short duration strength tests put a number on this: a small effect for lower limb exercises such as the squat and leg press (effect size about 0.24, across 60 trials) and a similar small effect for upper limb exercises such as the bench press (effect size about 0.32, across 53 trials). A separate pooled analysis that used direct imaging, MRI, CT or ultrasound, rather than scales or a DXA scan, found a much smaller hypertrophy effect (about 0.11) whose confidence interval crosses zero, so that particular imaging based estimate is less certain than the strength result, though it points the same direction and was larger in younger adults. These two strength estimates were checked against the Lanhers 2015 and 2017 abstracts, not the full methods. Their full-text appraisal and funding declarations remain outstanding.

In older adults specifically, pooled trials find roughly a kilogram more lean tissue and moderate gains in chest and leg press strength over training with a placebo. Not everyone responds the same way: a small randomised trial found that vegetarians, who tend to start with lower muscle creatine stores than people who eat meat, gained more muscle creatine and more from training when they supplemented, compared with people who eat meat given the same protocol. Baseline muscle creatine and diet are one real reason some people respond more than others. A newer 2026 trial in vegans found the same direction for body composition and lower body power over four weeks (more muscle, less fat, better jump height with creatine), though it did not find a significant extra strength benefit specifically, so this is a real but still developing picture rather than a settled one. Both dietary-pattern trials were small (42 participants in the vegetarian trial and 20 in the four-week vegan trial), so they do not settle how diet changes response. The vegan trial’s own funding and conflict declarations have not been read. One author also appears on other creatine papers with disclosed industry relationships; that does not establish this trial’s funding.

Is it safe?

Kidneys

In adults without kidney disease, the doses people normally use have not been shown to harm kidney function. A position stand reports that supplementation up to 30 g/day for 5 years has been well tolerated in healthy people, and a review focused on renal safety concluded that creatine at 5 to 30 g/day appears to have no detrimental effects on kidney function of individuals without underlying renal diseases. This does not extend to people who already have kidney disease or reduced kidney function.

Two more recent pooled analyses of randomised trials, published in 2025 and 2026, reached the same conclusion using more direct kidney measures: a small rise in serum creatinine, but no significant change in urea or in estimated glomerular filtration rate. One of the two states plainly that it received no funding and its authors have no competing interests, and all its authors work in a kidney research centre with no stated tie to the supplement industry, which is a stronger basis than shared affiliation alone, though a paper's own declaration is not the same as independent verification. The other could not be checked in full this pass because it sits behind a paywall, so its own funding and competing interest declarations are unread and its independence from industry is simply unknown.

The blood test catch

Creatine breaks down into a waste product called creatinine, the same thing a routine blood test measures to estimate kidney function. Taking creatine can nudge that number up without your kidneys working any less well: a two year trial found serum creatinine rose in the creatine group while more specific kidney markers such as cystatin C stayed normal. If you take creatine and have a blood test, tell whoever ordered it, do not stop the test.

Other common worries

  • Creatine is not an anabolic steroid and appears on neither the official 2026 WADA Prohibited List nor the 2026 Monitoring Program. Tested athletes should still manage supplement-contamination risk; batch testing reduces but does not eliminate it.
  • Some of the early weight gain is water held inside muscle cells; the evidence describes this as modest, and it is not the same as gaining fat.
  • Controlled evidence has not shown that creatine increases cramping or dehydration risk.
  • The hair-loss concern began with a small 2009 hormone study that did not measure hair. A 2025 twelve-week trial directly measured hair outcomes in 38 completing resistance-trained men and found no difference between 5 g/day of creatine and placebo. That is reassuring but cannot exclude small or long-term effects or generalise to all populations.

Who funds this research?

It is worth saying plainly, because it affects how much weight to put on some of the reassurance above. A good part of the creatine efficacy and dosing evidence, including the main safety position stand, comes from a recurring group of researchers who have disclosed financial ties to the creatine industry, mostly to AlzChem, the manufacturer behind the Creapure brand, and to the International Society of Sports Nutrition. Read from their own published declarations rather than guessed from affiliation: the position stand behind much of this article's dosing and safety information was itself funded by a supplement trade body, and several named authors across that stand and other sources here, including the single trial on hair loss, have disclosed paid advisory, consulting or research relationships with creatine sellers. One 2026 study even carries a formal declaration of no conflicts while its own text separately discloses that a creatine manufacturer paid its publication costs and that a co author chairs a manufacturer supported advisory board, which is a useful reminder that a clean sounding declaration is not the same as a fully independent one. None of this means the findings are wrong. Not every source here shares this industry link: the kidney safety analysis by Naeini 2025, the strength and lean tissue analysis by Chilibeck 2017, and the cognition analysis by Xu 2024 declare no competing interests in their own published statements. Xu’s review reports funding from the National Natural Science Foundation of China. A paper's own declaration is not the same as an independent audit of it, and a clean declaration on one of those three questions says nothing about the other two. It does mean a reader deserves to know how concentrated the authorship and funding are in parts of this literature, rather than reading terms like 'position stand' or 'no conflicts declared' as proof of independence.

If you do take it

  • Form: plain creatine monohydrate. Advanced forms (hydrochloride, buffered, liquid) cost more and have not been shown to work better.
  • Dose: around 3 to 5 g per day.
  • Loading: optional. A loading phase fills muscle stores faster; skipping it just means it takes a few weeks longer to reach the same place.
  • Timing: taking it at a consistent time matters more than a specific time relative to training.
  • The buy nothing version: a supermarket own brand creatine monohydrate that meets a recognised purity standard does the same job as a premium tub.

What about brain benefits?

Creatine's cognitive benefits are not established. Some reviews report memory benefits, but EFSA identified double-counting of participants in Xu's pooled analysis and did not accept it as support for the proposed cognition claim. Its 2024 assessment found that the submitted evidence did not establish a causal cognitive benefit. This does not prove that nobody could benefit, but it prevents us from presenting the pooled memory result as a settled benefit or an NST-endorsed moderate-confidence finding. Xu's 2025 correction clarifies attention and processing-speed scores; it does not resolve that separate statistical criticism. On this evidence, brain-benefit claims are not a sound reason for a healthy younger adult to start taking creatine.

The authors of the earlier memory review also corrected their analysis. Its overall result was no longer statistically significant, while a signal remained in older adults. They cautioned that the older-adult finding involved limited participant numbers and needed further trials.

Who should check with a clinician first

This is general information, not medical advice. Speak to a doctor or pharmacist before using creatine if you have kidney disease or reduced kidney function, a single kidney, are pregnant or breastfeeding, are under 18, take medicines that affect the kidneys, or have a chronic health condition. Severe or one-sided muscle pain, unexplained swelling or dark urine requires urgent medical assessment regardless of creatine use; simply stopping a supplement is not a substitute for assessment.

Practical meaning

Creatine monohydrate is a low cost, well studied small extra for people who already train. If you take it, use plain monohydrate at 3 to 5 g a day, be consistent, and do not pay more for other forms. If you would rather not take anything, you are not missing much: training hard enough, often enough, and eating enough total protein does the heavy lifting.

Limitations and uncertainty

Effects are generally small and response varies; a small trial suggests vegetarians respond more, consistent with their lower starting muscle creatine. Most safety evidence is in healthy adults. Creatine can affect serum creatinine and creatinine-derived kidney estimates without necessarily indicating kidney injury; two 2025/2026 pooled analyses confirm no significant change in the more direct measures (urea, eGFR); one (Naeini 2025) declared no funding and no competing interests in its own published statement, a stronger basis than affiliation alone though still a self-declaration, not independent verification; the other (Tsiaras 2026) is behind a paywall this pass could not access, so even that self-declared basis is missing for it. Neither includes trials longer than about a year or people with existing kidney disease. Hair outcomes have been tested directly in one small, short trial in trained men; broader and longer-term evidence is still needed. This article does not test or recommend products. Cognitive benefit is not established; pooled results face a specific double-counting criticism and need methodological reconciliation. These two strength estimates were checked against the Lanhers 2015 and 2017 abstracts, not the full methods. Their full-text appraisal and funding declarations remain outstanding. Both dietary-pattern trials were small (42 participants in the vegetarian trial and 20 in the four-week vegan trial), so they do not settle how diet changes response. The vegan trial’s own funding and conflict declarations have not been read. One author also appears on other creatine papers with disclosed industry relationships; that does not establish this trial’s funding.

No product needed

This page is here to answer the question, not force a product.

Some research pages are deliberately product-free because adding a retailer link would not help the reader make a better decision. When a product is genuinely relevant, it appears after the evidence and is clearly labelled.

Evidence behind this page

What the evidence says, and where it stops.

Creatine plus resistance training on strength and muscle/lean mass

moderate confidence

When added to resistance training, creatine monohydrate produces a small increase in strength and a small increase in muscle or lean mass over training plus placebo. Pooled short duration strength tests show a small effect for both lower limb exercises (effect size about 0.24, 60 trials) and upper limb exercises (effect size about 0.32, 53 trials). A separate pooled analysis using direct imaging (MRI, CT or ultrasound) found a very small hypertrophy effect (about 0.11) whose confidence interval crosses zero, so the imaging based muscle size result is less certain than the strength result. In older adults specifically, pooled trials show roughly a kilogram more lean tissue and moderate strength gains over placebo. The effect is real but modest, is an add on to training rather than a substitute, and varies between individuals: a small randomised trial found vegetarians, who start with lower muscle creatine stores, gain more from supplementation than people who eat meat on the same protocol.

Study context and sources
Who it may apply to
Healthy adults undertaking resistance training, including trained and untrained, younger and older adults, postmenopausal women, and one small trial specifically comparing vegetarians and people who eat meat. Not clinical populations.
Limitations
Effect sizes are small and trials vary in length, dose, training programme and how muscle was measured. The imaging based hypertrophy pooled effect (about 0.11) has a confidence interval crossing zero, so it should not be read as a clearly significant result on its own; the strength pooled effects are more consistent. The vegetarian comparison rests on one small 2003 trial (n=42 across four groups) not replicated at this scale since. Several cited author groups (Chilibeck, Candow, Forbes) publish together repeatedly across these sources; that overlap does not itself invalidate the findings but should be weighed when assessing independence of evidence. Response is individual and some people gain little. Several sources behind the strength and muscle claims share a recurring set of authors with disclosed financial ties to the creatine industry, mainly AlzChem (the manufacturer of the Creapure brand) and the ISSN: this applies to the position stand, the imaging based hypertrophy pooled analysis, and the older adult dosing review, each verified from its own full text and declaration, not merely inferred from affiliation. Chilibeck 2017 and Xu 2024's cognition analysis are the clearer exceptions, both declaring no conflicts from their own stated declarations. Disclosed conflicts do not make a finding wrong, but a reader should know how concentrated the authorship and industry funding are in this specific literature. These two strength estimates were checked against the Lanhers 2015 and 2017 abstracts, not the full methods. Their full-text appraisal and funding declarations remain outstanding. Both dietary-pattern trials were small (42 participants in the vegetarian trial and 20 in the four-week vegan trial), so they do not settle how diet changes response. The vegan trial’s own funding and conflict declarations have not been read. One author also appears on other creatine papers with disclosed industry relationships; that does not establish this trial’s funding.

Creatine and kidney function in healthy adults

moderate confidence

In adults without kidney disease, creatine at the doses people normally use has not been shown to harm kidney function. Two pooled analyses of randomised trials published in 2025 and 2026 both found a small rise in serum creatinine with supplementation but no significant change in urea or in estimated glomerular filtration rate, the more direct measures of kidney function. Of the two, Naeini 2025's full text was read this pass: its authors state no funding and no competing interests, and all five are affiliated with a kidney research centre in Iran with no stated industry tie, which is a stronger basis than affiliation alone, though a paper's own declaration is not the same as independent verification. Tsiaras 2026's full text could not be accessed (the journal is not open access), so its funding and conflict of interest declarations are unread and its independence from industry is simply unknown; its Greek university hygiene/nephrology affiliation does not tell us either way, pending a reviewer with journal access. The rise in serum creatinine is explained as a marker artefact (creatine breaks down to creatinine) rather than reduced kidney function; a separate two year trial in an older population found the same pattern, with a more specific marker, cystatin C, staying normal. This reassurance does not extend to people with existing kidney disease or reduced kidney function, and the longest included trials run only just over a year.

Study context and sources
Who it may apply to
Healthy adults without renal disease. Long term data are limited; the two year creatinine artefact observation comes from an aged Parkinson's cohort and is used only for that narrow point.
Limitations
No long term RCTs beyond about one year, and none in people with existing kidney disease; both 2025/2026 pooled analyses explicitly call for longer trials. The renal safety narrative review covers multiple supplements, not creatine alone. Do not generalise beyond healthy adults. Conflict of interest appraisal is asymmetric across the two newest sources: Naeini 2025 declared no funding and no competing interests in its own published statement (stronger than affiliation alone, but still self reported, not independently audited); Tsiaras 2026's declarations were not accessible this pass and should not be assumed clean on affiliation alone.

Creatine and hair loss

low confidence

The concern began with a small 2009 study that measured hormones rather than hair. A 2025 randomized trial directly measured several hair outcomes in 38 completing resistance-trained men and found no group-by-time differences after 5 g/day for 12 weeks. This is reassuring but cannot exclude small or long-term effects or generalise to women, older adults or people with androgenetic alopecia.

Study context and sources
Who it may apply to
A 2009 crossover study in 20 college-aged male rugby players and a 2025 twelve-week randomized trial with 38 completing resistance-trained men.
Limitations
Both studies are small, short and male-only. The direct trial cannot rule out smaller or longer-term effects or establish general safety across populations; conflict of interest appraisal is no longer an open item: three of the twelve authors on the 2025 trial disclosed creatine-industry ties (a scientific advisor to a creatine brand who has received manufacturer donations for research; the ISSN's CEO, who also advises two creatine or supplement brands; and an author who receives industry research support and owns a supplement industry consulting firm). That does not mean the trial's null result is wrong, but it is the single study behind this article's main hair-loss reassurance, so the disclosed pattern belongs in the article rather than only in this record.

Creatine and cognition

low confidence

Creatine's cognitive benefits are not established. Some reviews report memory benefits, but EFSA identified double-counting of participants in Xu's pooled analysis and did not accept it as support for the proposed cognition claim. Its 2024 assessment found that the submitted evidence did not establish a causal cognitive benefit. This does not prove that nobody could benefit, but it prevents us from presenting the pooled memory result as a settled benefit or an NST-endorsed moderate-confidence finding. Xu's 2025 correction clarifies attention and processing-speed scores; it does not resolve that separate statistical criticism. On this evidence, brain-benefit claims are not a sound reason for a healthy younger adult to start taking creatine. The authors of the earlier memory review also corrected their analysis. Its overall result was no longer statistically significant, while a signal remained in older adults. They cautioned that the older-adult finding involved limited participant numbers and needed further trials.

Study context and sources
Who it may apply to
Adults across different ages and health states; no subgroup benefit endorsed pending reconciliation.
Limitations
Correlated-outcome pooling and inflated participant counts identified by EFSA 2024 and Citherlet 2026. Do not adopt the original moderate memory grade as NST certainty. EFSA evaluated a specific proposed claim; its conclusion does not prove no possible benefit. Prokopidis author-accepted reply now read: overall SMD 0.19 (95% CI -0.07 to 0.46), with an older-adult signal based on limited participants. Text checked, not a re-run of the analysis; referenced figures were not present. Funding declarations do not resolve statistical limitations.

Related research, practical guidance, and comparisons to help with your next decision.

Compare options

Adjustable vs fixed dumbbells: which fits your home setup?

A practical comparison of storage, weight changes, increments and handling guidance. No direct trial comparing the formats was identified, so the decision stays focused on your space, loading needs and training style.

Last verified

Research

Should you stretch before exercising?

Static stretching can improve range of motion, but it is not the whole warm-up. Long holds can briefly reduce isolated maximal force; updated evidence does not support a blanket ban on stretching before sport.

Last verified